TY - GEN
AU - Reagan-Udall Foundation for the FDA
A1 - 
C4 - This grey literature reference is included in the Academy's Literature Collection in keeping with our mission to gather all sources of information on integration. Grey literature is comprised of materials that are not made available through traditional publishing avenues. Often, the information from unpublished resources can be limited and the risk of bias cannot be determined.
C5 - Grey Literature; Opioids & Substance Use
CY - Washington, D.C.
M1 - Generic
PB - Reagan-Udall Foundation for the FDA
PP - Washington, D.C.
PY - 2022
RN - https://reaganudall.org/sites/default/files/2022-05/Clinical%20Trial%20Design%20for%20Stimulant%20Use%20Disorder%20Research.pdf
T1 - A Practical Research Agenda for Treatment Development for Stimulant Use Disorder - Meeting Summary: May 2022
TI - A Practical Research Agenda for Treatment Development for Stimulant Use Disorder - Meeting Summary: May 2022
U1 - Grey Literature; Opioids & Substance Use
U4 - This grey literature reference is included in the Academy's Literature Collection in keeping with our mission to gather all sources of information on integration. Grey literature is comprised of materials that are not made available through traditional publishing avenues. Often, the information from unpublished resources can be limited and the risk of bias cannot be determined.
U5 - https://reaganudall.org/sites/default/files/2022-05/Clinical%20Trial%20Design%20for%20Stimulant%20Use%20Disorder%20Research.pdf
UR - https://reaganudall.org/sites/default/files/2022-05/Clinical%20Trial%20Design%20for%20Stimulant%20Use%20Disorder%20Research.pdf
Y1 - 2022
ER -